Savior Lifetec

Savior Lifetec PEG

The PEG Ratio (Price/Earnings-to-Growth) of Savior Lifetec (4167.TWO) as of Oct 24, 2026 is 0.06. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.16 — a change of -66.07% (lower).

PEG

0.06

YoY

-66.07%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Savior Lifetec is 2025 0.06 . PEG Ratio (Price/Earnings-to-Growth) of Savior Lifetec was 2024 0.16 . It decreases by -66.07% lower compared to the previous year.

The Savior Lifetec PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2017
1.35 TWD
Jan 1, 2020
0.12 TWD
Jan 1, 2022
1.46 TWD
Jan 1, 2023
1.00 TWD
Jan 1, 2024
0.16 TWD
Jan 1, 2025
0.06 TWD
The Savior Lifetec PEG history
YEARPEGYoY
0.06-66.07%
0.16-83.53%
1.00-31.35%
1.46+1,117.21%
0.12-91.12%
1.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

PEG Ratio (Price/Earnings-to-Growth) of Savior Lifetec is 0.06 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Savior Lifetec changed from 0.16 to 0.06, representing a -66.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Savior Lifetec with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Savior Lifetec

All Key Metrics — Savior Lifetec